Eagle Health Investments LP Has $55.74 Million Position in argenex SE $ARGX

Eagle Health Investments LP boosted its holdings in argenex SE (NASDAQ:ARGX) by 21.7% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 76,336 shares of the company’s stock after buying an additional 13,606 shares during the quarter. argenex accounts for 9.7% of Eagle Health Investments LP’s holdings, making the stock its largest position. Eagle Health Investments LP’s holdings in argenex were worth $55,744,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Oppenheimer & Co. Inc. raised its position in shares of argenex by 2.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock worth $372,000 after purchasing an additional 12 shares during the period. Valeo Financial Advisors LLC increased its stake in argenex by 0.9% in the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock worth $1,153,000 after purchasing an additional 12 shares in the last quarter. CI Investments Inc. raised its holdings in argenex by 2.6% during the 4th quarter. CI Investments Inc. now owns 469 shares of the company’s stock worth $394,000 after buying an additional 12 shares during the period. Allworth Financial LP boosted its holdings in shares of argenex by 12.7% in the fourth quarter. Allworth Financial LP now owns 115 shares of the company’s stock worth $97,000 after buying an additional 13 shares during the period. Finally, WPG Advisers LLC increased its position in shares of argenex by 17.8% in the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after acquiring an additional 13 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Citizens Jmp reduced their price target on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating for the company in a research report on Friday. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a report on Saturday. Guggenheim raised their target price on argenex from $1,135.00 to $1,185.00 and gave the stock a “buy” rating in a research report on Friday. Bank of America lifted their price target on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Finally, Royal Bank Of Canada increased their price objective on argenex from $945.00 to $1,025.00 and gave the stock an “outperform” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,054.11.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx agreed to acquire Forte Biosciences (NASDAQ: FBRX) for $77 per share in cash, representing an equity value of approximately $2.2 billion and a 41% premium to Forte’s prior closing price. The transaction gives argenx full ownership of FB102, an experimental autoimmune therapy. argenx acquisition announcement
• Positive Sentiment: FB102’s Phase 1b data in vitiligo and celiac disease reportedly support CD122 biology and a potential “pipeline-in-a-product” opportunity targeting pathogenic T-cell and NK-cell activity in diseases with significant unmet need. The acquisition broadens argenx’s immunology pipeline beyond its existing portfolio. argenx Forte acquisition details
• Positive Sentiment: Analyst sentiment remains supportive in parts of the market: Robert W. Baird raised its price target to $932, while HC Wainwright increased its earnings estimates. A separate Oppenheimer report had previously lifted its target to $1,037.
• Neutral Sentiment: Baird maintained a “neutral” rating despite the higher target, implying that the acquisition’s long-term value is not yet fully reflected in near-term expectations. Baird price target report
• Negative Sentiment: The all-cash $2.2 billion transaction represents a substantial capital commitment for a clinical-stage asset. Investors may be concerned about integration costs, future development spending and the risk that FB102’s early-stage results do not translate into successful late-stage trials or commercialization. One analysis consequently rated the stock “Hold.” Forte and argenx investment analysis

argenex Stock Performance

Shares of NASDAQ ARGX opened at $888.82 on Tuesday. The business has a 50 day simple moving average of $870.53 and a 200 day simple moving average of $815.82. argenex SE has a 52 week low of $590.78 and a 52 week high of $953.58. The stock has a market cap of $55.60 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 1.21 and a beta of 0.45.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, beating the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. On average, analysts predict that argenex SE will post 26.95 EPS for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.